Literature DB >> 31403858

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.

Krishnansu S Tewari1, Bradley J Monk2,3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31403858      PMCID： PMC7098831          DOI： 10.1200/JCO.18.02303

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  65 in total

1.  Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model.

Authors:  K S Tewari; J A Taylor; S Y Liao; P J DiSaia; R A Burger; B J Monk; C C Hughes; L P Villarreal
Journal:  Gynecol Oncol       Date:  2000-04       Impact factor: 5.482

2.  Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Marth; F Landoni; S Mahner; M McCormack; A Gonzalez-Martin; N Colombo
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

3.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

Authors:  C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

4.  Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Authors:  Jean-Sebastien Frenel; Christophe Le Tourneau; Bert O'Neil; Patrick A Ott; Sarina A Piha-Paul; Carlos Gomez-Roca; Emilie M J van Brummelen; Hope S Rugo; Shari Thomas; Sanatan Saraf; Reshma Rangwala; Andrea Varga
Journal:  J Clin Oncol       Date:  2017-11-02       Impact factor: 44.544

5.  A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).

Authors:  P H Thaker; R Salani; W E Brady; H A Lankes; D E Cohn; D G Mutch; R S Mannel; K M Bell-McGuinn; P A Di Silvestro; D Jelovac; J S Carter; W Duan; K E Resnick; D S Dizon; C Aghajanian; P M Fracasso
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

6.  Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.

Authors:  Zhigang Kang; Sanja Stevanović; Christian S Hinrichs; Liang Cao
Journal:  Clin Cancer Res       Date:  2017-09-12       Impact factor: 12.531

Review 7.  Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.

Authors:  Enrica Bentivegna; Sebastien Gouy; Amandine Maulard; Cyrus Chargari; Alexandra Leary; Philippe Morice
Journal:  Lancet Oncol       Date:  2016-06       Impact factor: 41.316

8.  A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.

Authors:  A P Kudelka; T Levy; C F Verschraegen; C L Edwards; S Piamsomboon; W Termrungruanglert; R S Freedman; A L Kaplan; D G Kieback; C A Meyers; K A Jaeckle; E Loyer; M Steger; R Mante; G Mavligit; A Killian; R A Tang; J U Gutterman; J J Kavanagh
Journal:  Clin Cancer Res       Date:  1997-09       Impact factor: 12.531

9.  A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.

Authors:  Chien-Sheng Tsai; Chyong-Huey Lai; Ting-Chang Chang; Tzu-Chen Yen; Koon-Kwan Ng; Swei Hsueh; Steve P Lee; Ji-Hong Hong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-21       Impact factor: 7.038

10.  A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.

Authors:  Toru Sugiyama; Mika Mizuno; Yoichi Aoki; Manabu Sakurai; Tadaaki Nishikawa; Eisuke Ueda; Kosei Tajima; Nobuhiro Takeshima
Journal:  Jpn J Clin Oncol       Date:  2016-10-07       Impact factor: 3.019
View more
  9 in total

Review 1.  Intensified Systemic Therapy Regimens in Combination With Definitive Radiation for Treatment of Cervical Cancer.

Authors:  Travis T Sims; Ann H Klopp
Journal:  Semin Radiat Oncol       Date:  2020-10       Impact factor: 5.934

2.  Should adjuvant chemotherapy be formally studied among patients found to have pelvic lymph node metastases following radical hysterectomy with lymphadenectomy for early-stage cervical cancer?

Authors:  Alyssa C Bujnak; Krishnansu S Tewari
Journal:  J Gynecol Oncol       Date:  2021-04-19       Impact factor: 4.401

3.  Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.

Authors:  Ana Oaknin; Claire F Friedman; Lynda D Roman; Anishka D'Souza; Irene Brana; François-Clement Bidard; Jonathan Goldman; Edwin A Alvarez; Valentina Boni; Adam C ElNaggar; Rodolfo Passalacqua; Khanh T M Do; Alessandro D Santin; Kiana Keyvanjah; Feng Xu; Lisa D Eli; Alshad S Lalani; Richard P Bryce; David M Hyman; Funda Meric-Bernstam; David B Solit; Bradley J Monk
Journal:  Gynecol Oncol       Date:  2020-07-25       Impact factor: 5.482

4.  Therapeutic vaccination using HPV 16 E7 to eradicate CIN3.

Authors:  Krishnansu S Tewari
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

5.  Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.

Authors:  Wenjuan Chen; Siyi Xiu; Xingyun Xie; Huiming Guo; Yuanji Xu; Penggang Bai; Xiaoyi Xia
Journal:  Radiat Oncol       Date:  2022-01-10       Impact factor: 3.481

6.  Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models.

Authors:  Ha-Yeon Shin; Eun-Ju Lee; Wookyeom Yang; Hyo Sun Kim; Dawn Chung; Hanbyoul Cho; Jae-Hoon Kim
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

Review 7.  Enhancement of Conventional and Photodynamic Therapy for Treatment of Cervical Cancer with Cannabidiol.

Authors:  Radmila Razlog; Cherie Ann Kruger; Heidi Abrahamse
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

8.  Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification.

Authors:  Kai Sun; Jing-Zhang Li; Zhan-Xiong Luo; Cheng Huang
Journal:  World J Surg Oncol       Date:  2022-10-17       Impact factor: 3.253

9.  Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Authors:  Krishnansu S Tewari; Michael W Sill; Bradley J Monk; Richard T Penson; David H Moore; Heather A Lankes; Lois M Ramondetta; Lisa M Landrum; Leslie M Randall; Ana Oaknin; Mario M Leitao; Eric L Eisenhauer; Paul DiSilvestro; Linda Van Le; Michael L Pearl; James J Burke; Ritu Salani; Debra L Richardson; Helen E Michael; David W Kindelberger; Michael J Birrer
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.